Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
41.3Last Year’s EPS
43.1Same Quarter Last Year
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: 6.04%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and growth in specialty medicines, particularly in oncology and HIV segments. However, the vaccines segment faced challenges, and there were significant legal costs from the Zantac litigation. The company remains optimistic about future growth, supported by a robust pipeline and shareholder return strategies.Company Guidance
In the recent call, GSK provided comprehensive guidance for 2024 and beyond, highlighting several key metrics and strategic initiatives. The company reported an 8% increase in sales, reaching over £31 billion, with Specialty medicines experiencing double-digit growth across all therapy areas, contributing significantly to this performance. Core operating profit rose by 13%, while core EPS increased by 12%. These results led to two upgrades in 2024 guidance and supported an increased dividend of 61p per share. Looking forward, GSK anticipates 2025 to be another year of profitable growth, driven by Specialty medicines, with sales projected to grow between 3% and 5%, and core operating profit and EPS expected to rise between 6% and 8%. By 2031, GSK forecasts risk-adjusted sales of more than £40 billion, with Specialty medicines accounting for more than 50% of sales. Additionally, GSK plans to buy back up to £2 billion of shares over the next 18 months, reflecting its strong cash generation and commitment to enhancing shareholder returns.Strong Financial Performance
Sales grew 8% to over £31 billion, core operating profit was up 13%, and core EPS was up 12%. Dividend increased to 61p per share.
Specialty Medicines Growth
Specialty medicines grew 19%, with oncology sales nearly doubling to more than £1.4 billion.
HIV Segment Success
HIV sales grew 13%, with significant contributions from long-acting injectables, Cabenuva and Apretude.
Pipeline and R&D Achievements
13 positive Phase 3 readouts, focus on 14 scale opportunities with potential sales above £2 billion.
Shareholder Returns
Announcement of a £2 billion share buyback over the next 18 months.
---
GB:GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | 1364.64p | 1468.47p | +7.61% |
| Oct 30, 2024 | 1419.54p | 1376.02p | -3.07% |
| Jul 31, 2024 | 1494.37p | 1464.82p | -1.98% |
| May 01, 2024 | 1607.38p | 1638.13p | +1.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GlaxoSmithKline (GB:GSK) report earnings?
GlaxoSmithKline (GB:GSK) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is GlaxoSmithKline (GB:GSK) earnings time?
GlaxoSmithKline (GB:GSK) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of GlaxoSmithKline stock?
The P/E ratio of GlaxoSmithKline is N/A.
What is GB:GSK EPS forecast?
GB:GSK EPS forecast for the fiscal quarter 2025 (Q1) is 41.3.
---